Aaron Bhole is a first year med student at the Thomas Jefferson University Sidney Kimmel Medical College in Philadelphia. He is involved with a group at Jefferson called Physician Executive Leadership – or PEL – which is a HealthX like organization that focuses on developing future physician leaders.
We were able to hit on Aaron’s interest in the intersection of business and medicine, PEL, drug pricing, orphan drugs, and many other topics.
Register for the Penn HealthX conference happening THIS SUNDAY, December 2nd here:
http://pennhealthx.com/events/conference#Registration
Map
3:15 – Aaron’s time at Cornell, the 3+2 Program to get an MBA, and field ecology/cancer research
6:20 – getting interested in the “macro” of healthcare and the value of having an MBA before starting med school
9:30 – Physician Executive Leadership (PEL) at Jefferson Med
11:00 – Why should people care about rising drug prices?
15:40 – Generic Drugs, The Hatch Waxman Act
22:10 – Patent Life (~20 years) vs. Exclusivity (5-7 years, indication specific)
25:00 – How do companies decide how to price a drug?
30:15 – Negotiating drug prices? Would it work in the U.S? Spoiler – probably not
36:00 – Ryan’s thoughts on the patent system in the U.S
39:09 – Aaron’s response – improving how we incentivize “actual innovation” as opposed to marginal innovation
42:10 – Are current price transparency laws any good? (recent California law)
47:40 – Orphan Drugs – what are they? ; The Orphan Drug Act of 1983 – incentivizing the development of orphan drugs (small patient populations)
51:00 – Orphan drugs are expensive and the laws are being taken advantage of – “salami slicing”
56:45 – What is FDA (and Scott Gottlieb) doing now?
61:00 – Last few questions/wrap up
Links
GOP Tax plan may get rid of Orphan Drug R+D tax credit
https://www.npr.org/sections/health-shots/2017/11/03/561805484/house-republicans-aim-to-eliminate-tax-credits-for-orphan-drugs?sc=tw
Airspeed of a Swallow
https://www.youtube.com/watch?v=liIlW-ovx0Y
Physician Executive Leadership (PEL)
http://www.physicianexecutiveleadership.com/
Healthcare Spending Pie Chart (bit outdated)
http://bit.ly/2AEkSrz
Hatch-Waxman Act
https://en.wikipedia.org/wiki/Drug_Price_Competition_and_Patent_Term_Restoration_Act
A Primer of Acronyms and Different Drug Price “Types”
http://www.hivforum.org/storage/documents/2014/Geeneric_ARVs/cross_fchrgenerics_31mar14.pdf
Graphs showing How Much Brand Drug Price decreases with increasing Generic Competition
http://bit.ly/2Aezddo
Articles on How Gilead Chose to Price it’s HepC Drugs
http://bit.ly/2i0uguc
http://bit.ly/2BuHlnN
National Institute for Health and Care Excellence (NICE) – U.K
https://en.wikipedia.org/wiki/National_Institute_for_Health_and_Care_Excellence
ICER (Institute for Clinical and Economic Review) – U.S
https://icer-review.org/
Having Medicare Negotiate Drug Prices Probably Won’t Help (Articles)
http://www.latimes.com/business/hiltzik/la-fi-hiltzik-medicaire-negotiate-20170111-story.html
https://www.statnews.com/2017/06/13/drug-prices-government-negotiation/
Is California’s Drug Price Transparency Law any good? These articles say no
https://www.healthaffairs.org/do/10.1377/hblog20171002.062240/full/
http://www.drugchannels.net/2017/10/thanks-california-sb17-will-trigger.html
Orphan Drug Act of 1983
https://en.wikipedia.org/wiki/Orphan_Drug_Act_of_1983
https://en.wikipedia.org/wiki/Orphan_drug
Orphan Drugs are Big Business
http://wapo.st/2iYgf0H
http://n.pr/2Ak2Esb
FDA Attempting to Get Rid of “Salami Slicing”
http://n.pr/2Bla0v0